Cosibelimab

Cosibelimab (CK-301) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy[1].

Product Specifications

CAS Number

[2216751-26-5]

Product Name Alternative

CK-301; TG-1501

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cosibelimab.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Cosibelimab]

Molecular Weight

(144.64 kDa)

References & Citations

[1]Akintunde Akinleye, et al. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019 Sep 5;12 (1) :92. |[2]Clingan P, et al., Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J Immunother Cancer. 2023 Oct;11 (10) :e007637.